Lonza has completed the validation of its new viral-induced cell processing GMP suites in Houston, TX, and has also completed the tech transfer process for a new virally-transfected T-cell product. Lonza said these new cell processing suites will allow it to develop virally-modified autologous cellular immunotherapies.
Lonza
Tuesday, 29 January 2013
Manufacturing starts at Lonza Houston
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment